Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS

Pemetrexed and platinum (PP) combination chemotherapy is the current standard first-line therapy for treatment of malignant mesothelioma (MM). However, a useful predictive biomarker for PP therapy is yet to be found. Here, we performed targeted exome sequencing to profile somatic mutations and copy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jeong Eun, Kim, Deokhoon, Hong, Yong Sang, Kim, Kyu-pyo, Yoon, Young Kwang, Lee, Dae Ho, Kim, Sang-We, Chun, Sung-Min, Jang, Se Jin, Kim, Tae Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884183/
https://www.ncbi.nlm.nih.gov/pubmed/29413759
http://dx.doi.org/10.1016/j.tranon.2018.01.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884183/
https://www.ncbi.nlm.nih.gov/pubmed/29413759
http://dx.doi.org/10.1016/j.tranon.2018.01.005

Ejemplares similares